Ionis, Genuity Science partner to advance RNA-targeted therapies

By The Science Advisory Board staff writers

October 1, 2020 -- Ionis Pharmaceuticals and Genuity Science have entered a multiyear collaboration to accelerate the discovery and development of genetically validated targets for up to 20 diseases.

The partnership will leverage Genuity's whole-genome sequencing and deep phenotypic data to better define underlying disease mechanisms. This will be paired with Ionis' proprietary antisense technology for direct translation of targets into RNA-targeted therapeutics.

Under the agreement, Genuity will receive a combination of upfront payments and development milestones plus product royalties.

Cartesian begins trial of RNA-based cell therapy for COVID-19
Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in...
Arrakis touts paper on RNA-targeted small molecules
Arrakis Therapeutics is touting the publication of a new paper that demonstrates the capabilities of its proprietary photoaffinity labeling/next-generation...
RNAimmune gets $2.35M for mRNA therapeutics, vaccines
RNAimmune has secured $2.35 million in seed round financing from multiple venture capital firms to advance its COVID-19 vaccine RV1730 program and...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter